Stock Events

Stock Events

uniQure N.V. 

€39.40
104
+€1.15+3.01% 19:56 Today

Statistics

Day High
39.4
Day Low
37.25
52W High
60.16
52W Low
7.37
Volume
-
Avg. Volume
-
Mkt Cap
2.73B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q1 2026
Q2 2026
Next
-1.06
-0.95
-0.83
-0.72
Expected EPS
-0.79351032953
Actual EPS
N/A

Financials

-1,249.34%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
13.81MRevenue
-172.55MNet Income

Analyst Ratings

50.30Average Price Target
The highest estimate is 60.70.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow UQ1.STU. It's not an investment recommendation.
NVIDIA
22
NVDA
Tesla
18
TSLA
Alphabet
18
GOOGL
Microsoft
17
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.88B
BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for rare genetic diseases, overlapping with uniQure's target market.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc., through its acquisition of Bamboo Therapeutics and Spark Therapeutics, has expanded into gene therapy, making it a competitor in the same field as uniQure.
Regenxbio
RGNX
Mkt Cap590.16M
REGENXBIO Inc. is a biotechnology company that develops AAV-based gene therapies for genetic and other diseases, competing in the same space as uniQure.
Sarepta Therapeutics
SRPT
Mkt Cap2.38B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based and gene therapy treatments for rare diseases, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.79B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a next-generation technology that could compete with uniQure's gene therapy approaches.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics AG focuses on the development of gene-based medicines using the CRISPR/Cas9 system, competing in the broader gene therapy and editing market alongside uniQure.

About

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Show more...
CEO
Matthew Kapusta
Employees
221
Country
Netherlands
ISIN
NL0010696654
WKN
000A1XDTV

Listings

MX
MX
QUREN.MX
STU
DE
UQ1.STU
XNAS
US
QURE
LSE
GB
0EE0.LSE

0 Comments

Share your thoughts

FAQ

What is uniQure N.V. stock price today?▼
The current price of UQ1.STU is €39.40 EUR — it has increased by +3.01% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
What is uniQure N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange uniQure N.V. stocks are traded under the ticker UQ1.STU.
Is uniQure N.V. stock price growing?▼
UQ1.STU stock has fallen by -4.48% compared to the previous week, the month change is a -1.5% fall, over the last year uniQure N.V. has showed a +166.58% increase.
What is uniQure N.V. market cap?▼
Today uniQure N.V. has the market capitalization of 2.73B
When is the next uniQure N.V. earnings date?▼
uniQure N.V. is going to release the next earnings report on November 10, 2026.
What were uniQure N.V. earnings last quarter?▼
UQ1.STU earnings for the last quarter are -1.06 EUR per share, whereas the estimation was -0.72 EUR resulting in a -48.37% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is uniQure N.V. revenue for the last year?▼
uniQure N.V. revenue for the last year amounts to 13.81M EUR.
What is uniQure N.V. net income for the last year?▼
UQ1.STU net income for the last year is -172.55M EUR.
How many employees does uniQure N.V. have?▼
As of September 08, 2026, the company has 221 employees.
In which sector is uniQure N.V. located?▼
uniQure N.V. operates in the Health & Wellness sector.
When did uniQure N.V. complete a stock split?▼
uniQure N.V. has not had any recent stock splits.
Where is uniQure N.V. headquartered?▼
uniQure N.V. is headquartered in AMSTERDAM, Netherlands.